Epoch Biodesign, a London-based BioTech startup specialising in enzymatic recycling technology, has closed a €10.3 million ($12 million) financing round to accelerate the commercialisation of its recycled nylon 6,6.
The investment includes participation from Lululemon, KOMPAS VC, Happiness Capital, Extantia, Leitmotif, and others. Last year, the company raised €17 million in Series A capital in an oversubscribed round led by Extantia Capital. With this latest funding, Epoch’s total capital raised exceeds €43.1 million ($50 million).
Jacob Nathan, Founder and CEO of Epoch Biodesign, said, “Nylon 6,6 is a key material for both apparel and automotive industries, but a circular solution has yet to be successful at scale. Support from partners such as these highlights Epoch’s momentum and will accelerate our plans to progress from multi-tonne production to multi-kilotonne scale. Very soon, recycled nylon 6,6 will be available to our partners in apparel, automotive and beyond.”
Founded in 2019, Epoch Biodesign combines artificial intelligence and advanced synthetic biology to design enzymes to efficiently recycle end-of-life plastic and textile waste at a commercial scale. Its ultra-low emission process produces virgin-quality recycled materials from mixed waste streams.
[...]